Partnering
Integrating partnerships and collaborations into our core business strategy
Working with great partners and collaborators forms a core part of our corporate strategy and allows us to expand and accelerate our efforts to bring novel multifunctional therapeutics to the broadest group of patients in the most efficient manner possible.
Our partnerships and collaborations focus on:
- Development and commercialization of current and future product candidates
- Clinical and research collaborations that broaden the potential of our internal antibody-drug conjugate (ADC) and multispecific antibody therapeutics (MSAT) platforms
- Collaborations with companies to access technologies and programs that are complementary to our internal ADC and MSAT capabilities
- Acquisition of external programs where our team can add scientific and development value and turn them into new royalty positions through partnerships
Connect with us
To explore partnership opportunities, please contact bd@zymeworks.com
Our Commercial Partners
Platform
Ziihera® (zanidatamab-hrii)
Azymetric | EFECT
Partner
Stage
Marketed
Potential Future Milestone Payments
Up to $1.36 billion
Royalty Rate
Tiered worldwide royalties between 10% to 20% other than in BeOne territories
Platform
Ziihera® (zanidatamab-hrii)
Azymetric | EFECT
Partner
Stage
Marketed
Potential Future Milestone Payments
Up to $144 million
Royalty Rate
Tiered royalties up to 19.5% of net sales in BeOne territories1
Our Technology Platform Collaborators
Platform
JNJ-78278343 CD3 x KLK2 Bispecific
Azymetric | EFECT
Partner
Stage
Phase 3
Potential Future Milestone Payments
Up to $434 million2
Royalty Rate
Tiered worldwide royalties in the mid-single digit percentages
Platform
Bispecific Antibody
Azymetric
Partner
Stage
Phase 1
Potential Future Milestone Payments
Up to $1.1 billion
Royalty Rate
Tiered worldwide royalties in the low to mid-single digit percentages
Platform
Bispecific Antibody
Azymetric | EFECT
Partner
Stage
Phase 1
Potential Future Milestone Payments
Up to $313 million
Royalty Rate
Tiered worldwide royalties on sales
Platform
Bispecific Antibody
Azymetric | EFECT
Partner
Stage
Phase 1
Potential Future Milestone Payments
Up to $230 million
Royalty Rate
Tiered worldwide royalties from low single digit percentages up to 10%
Platform
Bispecific Antibody
Azymetric | EFECT
Partner
Stage
Preclinical
Potential Future Milestone Payments
Up to $1.1 billion
Royalty Rate
Tiered worldwide royalties in the low single digit percentages
Platform
Bispecific Antibody
Azymetric | EFECT
Partner
Stage
Preclinical
Potential Future Milestone Payments
Up to $921.8 million
Royalty Rate
Tiered worldwide royalties on sales
- Tiered royalties of up to 19.5% of net sales in BeOne territories, increasing to up to 20% when cumulative amounts forgone as a result of a royalty reduction of 0.5% reaches a cap in the low double-digit millions of dollars.
- $1-$5B peak sales opportunity referenced by J&J: https://www.investor.jnj.com/pipeline/novel-therapies/default.aspx
Innovation
Pushing the boundaries of antibody-based therapeutics through novel multispecifics and optimized drug conjugates.
